Life Biosciences administers first partial OSKM reprogramming dose to glaucoma patient

The trial targets optic-nerve regeneration by transient expression of Oct4, Sox2, Klf4 and c-Myc. Prior mouse studies demonstrated restored axon density and visual evoked potentials after 2–4 weeks of doxycycline-inducible OSKM delivery without full dedifferentiation. The protocol limits factor expression to avoid teratoma formation observed in full reprogramming regimens.

Lopez-Otin et al. (Cell, 2013) listed nine hallmarks; telomere attrition and senescence each dominated sequential funding cycles before 2020. Reprogramming instead acts on the epigenetic maintenance module, resetting DNA-methylation clocks and histone marks rather than clearing p16-positive cells or extending telomeres. This mechanistic distinction explains why Altos Labs raised $3 billion and Retro Biosciences reached $1.8 billion valuation after $180 million from Altman.

NewLimit’s planned 2027 liver trial will measure H3K9me3 and methylation age in hepatocytes as primary endpoints. Success thresholds require at least 3-year epigenetic reversal sustained at 12 months post-dose. Regulatory precedent from ocular gene therapy may compress IND timelines for subsequent reprogramming indications.

Operational risk centers on vector immunogenicity and off-target gene activation; first-in-human safety data will determine whether partial reprogramming advances beyond ophthalmology.